• Go to navigation
  • Go to content
AstraZeneca Clinical Trials

Astrazeneca Worldwide

  • AstraZeneca Websites
AstraZeneca US

Main navigation

  • Home
  • Therapy Areas
    • Oncology/Infection
    • Cardiovascular
    • Gastrointestinal
    • Neuroscience
    • Respiratory/Inflammation
  • Drug Products
    • All Drug Products
  • Diseases & Conditions
    • All Diseases and Conditions
  • Glossary
  • Contact Us
  • Disclosure Commitment

You are here

  • Home
  • Total number of clinical trials

  • Expand All
  • Collapse All
  • Pages
  • Previous
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • Next
  • expand A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD4547 in Japanese Patients with Advanced Solid Malignancies
    Study Id
    D2610C00002
    Drug Name
    AZD4547
    Study Name
    D2610C00002
    Recruiting Status
    Closed
    Protocol Status
    Not Available
    Report Status
    Not Available
  • expand Observational study to understand patients’ and physicians’ attitudes to Statins in Turkey
    Study Id
    NIS-CTR-XXX-2012/1
    Disease
    hypercholesterolaemia
    Drug Name
    non drug study (cardiovascular)
    Recruiting Status
    Closed
    Protocol Status
    Not Available
    Report Status
    Not Available
  • expand Efficacy and tolerability study of Symbicort Turbuhaler(160/4.5μg/inhalation,2inhalations twice daily) added to Atrovent (20μg/inhalation, 2 inhalations 4 times daily)+theophylline SR(0.1g/tablet,1 tablet p.o. twice daily) compared with Atrovent+theophylline SR in severe COPD patients
    Study Id
    D589BL00022
    Disease
    chronic obstructive pulmonary disease
    Drug Name
    Symbicort Turbuhaler
    Study Name
    SECURE 2
    Recruiting Status
    Closed
    Protocol Status
    Not Available
    Report Status
    Not Available
  • expand A Phase I, Open-label, Multicentre, Dose Escalation Study to Assess the Safety and Tolerability, and Pharmacokinetics of AZD1480 in Asian Patients with Advanced Solid Malignancies and Asian Patients with Child-Pugh A to B7 Advanced Hepatocellular Carcinoma (HCC) in the escalation phase, EGFR or ROS mutant NSCLC and non-smokers with lung metastasis and gastric cancer and solid tumour with biopsy available in the expansion phase.
    Study Id
    D1060C00004
    Disease
    hepatocellular carcinoma
    Drug Name
    AZD1480
    Study Name
    D1060C00004
    Recruiting Status
    Closed
    Protocol Status
    Not Available
    Report Status
    Not Available
  • expand An Open-label, Single-center, 2-Part, Randomized Study to Assess the Pharmacokinetics of R406 in Healthy Subjects when Fostamatinib 150 mg is Administered Alone in Fed and Fasted state and in Combination with Ranitidine in Fasted State, and to Assess the Relative Bioavailability of Process Variants of Tablets
    Study Id
    D4300C00019
    Disease
    pharmacokinetics
    Drug Name
    Fostamatinib Disodium
    Study Name
    D4300C00019
    Recruiting Status
    Closed
    Protocol Status
    Not Available
    Report Status
    Not Available
  • expand A Phase I, Single-centre, Open-label, Partly Randomised, Cross-over Single Dose Study in Healthy Volunteers to Evaluate the Absolute Pulmonary Bioavailability of AZD8683 when Administered Inhaled via a New Dry Powder Inhaler and via Turbuhaler™
    Study Id
    D1883C00008
    Disease
    pharmacokinetics
    Drug Name
    AZD8683
    Study Name
    D1883C00008
    Recruiting Status
    Closed
    Protocol Status
    Not Available
    Report Status
    Not Available
  • expand A randomised, double-blind placebo- and active-controlled, multi-centre, 6-way cross-over, single-dose phase IIa study to investigate the bronchodilatory and systemic effects of 4 different doses of inhaled AZD8683 in patients with Chronic Obstructive Pulmonary Disease (COPD)
    Study Id
    D1883C00007
    Disease
    chronic obstructive pulmonary disease
    Drug Name
    AZD8683
    Study Name
    D1883C00007
    Recruiting Status
    Closed
    Protocol Status
    Not Available
    Report Status
    Not Available
  • expand A Double Masked, Placebo Controlled, Randomised, Parallel Group Phase IIa Study to assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-Ocular Pressure
    Disease
    hypertension
    Drug Name
    AZD4017
    Recruiting Status
    Closed
    Protocol Status
    Not Available
    Report Status
    Not Available
  • expand Effectiveness of risk minimisation interventions for ticagrelor in Canada
    Study Id
    D5130L00009
    Disease
    acute coronary syndrome
    Drug Name
    Brilinta
    Study Name
    D5130L00009
    Recruiting Status
    Closed
    Protocol Status
    Not Available
    Report Status
    Not Available
  • expand Metabolic changes in prostate cancer patients with Androgen-ablation therapy (AAT)
    Study Id
    NIS-OES-DUM-2010/1
    Disease
    prostate cancer
    Drug Name
    non drug study (oncology)
    Study Name
    NIS-OES-DUM-2010/1
    Recruiting Status
    Closed
    Protocol Status
    Not Available
    Report Status
    Not Available
  • Pages
  • Previous
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • Next
  • Expand All
  • Collapse All

Page tools

  • Print
  • Bookmark this page

Legal notices

  • Legal notice
  • Privacy policy
  • © AstraZeneca 2013